Ionis Pharmaceuticals (IONS) News Today $38.76 +0.37 (+0.96%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by abrdn plcabrdn plc grew its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 22.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 303,274 shares of the company's stock after buying an additional 56,357 shareNovember 2 at 4:14 AM | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Significant Decrease in Short InterestNovember 1 at 4:43 AM | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest Down 6.3% in OctoberIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 9,870,000 shares, a decline of 6.3% from the September 30th total of 10,530,000 shares. Currently, 6.8% of the shares of the stock are sold short. Based on an average trading volume of 1,570,000 shares, the days-to-cover ratio is presently 6.3 days.October 31 at 10:59 AM | marketbeat.comInternational Assets Investment Management LLC Boosts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)International Assets Investment Management LLC grew its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 3,287.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 328,772 shares of the company's stocOctober 31 at 3:31 AM | marketbeat.comIonis Pharmaceuticals (IONS) Set to Announce Quarterly Earnings on WednesdayIonis Pharmaceuticals (NASDAQ:IONS) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638986)October 30 at 7:19 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Downgraded to Sell at StockNews.comOctober 28, 2024 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Rating Lowered to Sell at StockNews.comStockNews.com lowered shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday.October 25, 2024 | marketbeat.comIonis: Expect More Of The Same In Terms Of Earnings, Despite Regulatory SuccessesOctober 25, 2024 | seekingalpha.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of "Moderate Buy" by AnalystsOctober 25, 2024 | americanbankingnews.comIonis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three yearsOctober 24, 2024 | finance.yahoo.comIonis to hold third quarter 2024 financial results webcastOctober 23, 2024 | prnewswire.comIonis Pharmaceuticals (IONS) Receives a Buy from TD CowenOctober 21, 2024 | markets.businessinsider.comWAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosisOctober 21, 2024 | prnewswire.comQ3 2024 Earnings Forecast for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Issued By Leerink PartnrsIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Leerink Partnrs raised their Q3 2024 EPS estimates for Ionis Pharmaceuticals in a report issued on Monday, October 14th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($0.91) for the quartOctober 17, 2024 | marketbeat.comSanctuary Advisors LLC Takes Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Sanctuary Advisors LLC acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,441 shares ofOctober 13, 2024 | marketbeat.comMillennium Management LLC Decreases Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Millennium Management LLC trimmed its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 78.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 128,215 shares of the company's stock after selling 454,964October 11, 2024 | marketbeat.comDimensional Fund Advisors LP Decreases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Dimensional Fund Advisors LP reduced its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 18.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 88,746 shares of the company's stock after selliOctober 10, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge FundsOctober 9, 2024 | msn.comIONS Factor-Based Stock AnalysisOctober 4, 2024 | nasdaq.comNew positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingOctober 3, 2024 | prnewswire.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Clearbridge Investments LLCClearbridge Investments LLC cut its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 51.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 2,160,270 shares of the company's stock after selling 2,305,921 shares during the perioOctober 3, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. cut its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 52.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 137,210 shares of the company's stock afterOctober 2, 2024 | marketbeat.comIonis Gets FDA Fast-Track Designation for Zilganersen in Alexander DiseaseOctober 1, 2024 | marketwatch.comIonis Pharma Says FDA Grants Fast Track Designation For Zilganersen To Treat Alexander DiseaseOctober 1, 2024 | markets.businessinsider.comZilganersen granted U.S. FDA Fast Track designation for people living with Alexander diseaseOctober 1, 2024 | prnewswire.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by Algert Global LLCAlgert Global LLC raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 149.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 75,350 shares of the company's stOctober 1, 2024 | marketbeat.comMarshall Wace LLP Acquires 157,756 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Marshall Wace LLP increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 1,021.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 173,199 shares of the company's stock after acquiringSeptember 30, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of "Moderate Buy" from BrokeragesIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) has received an average rating of "Moderate Buy" from the twenty research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twelveSeptember 30, 2024 | marketbeat.comSusquehanna Portfolio Strategies LLC Sells 87,958 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Susquehanna Portfolio Strategies LLC lessened its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 67.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,028 shares of theSeptember 29, 2024 | marketbeat.comIonis Pharmaceuticals: A Strong Buy on Promising Pipeline and Strategic Financial HealthSeptember 27, 2024 | markets.businessinsider.comDeep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)September 27, 2024 | benzinga.comSquarepoint Ops LLC Decreases Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Squarepoint Ops LLC cut its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 41.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 436,818 shares of the company's stock after sellingSeptember 27, 2024 | marketbeat.comIonis Pharmaceuticals' (IONS) Outperform Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday.September 26, 2024 | marketbeat.comGreat Point Partners LLC Invests $15.73 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Great Point Partners LLC purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 330,000 shares of the company's stock, valued at approSeptember 24, 2024 | marketbeat.comRenaissance Technologies LLC Purchases 69,800 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Renaissance Technologies LLC boosted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 38.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 249,514 shares of the company's stock after acquSeptember 23, 2024 | marketbeat.comDRW Securities LLC Makes New $2.43 Million Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)DRW Securities LLC purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 50,956 shares of the company'September 22, 2024 | marketbeat.comState of New Jersey Common Pension Fund D Sells 26,498 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)State of New Jersey Common Pension Fund D lowered its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 32.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,349September 19, 2024 | marketbeat.comPrincipal Financial Group Inc. Lowers Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Principal Financial Group Inc. lowered its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 41.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,458 shares of the company's stock aftSeptember 14, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX), MoonLake Immunotherapeutics (MLTX) and Ionis Pharmaceuticals (IONS)September 13, 2024 | markets.businessinsider.comQ3 2024 EPS Estimates for Ionis Pharmaceuticals, Inc. Raised by Leerink Partnrs (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at Leerink Partnrs boosted their Q3 2024 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research report issued on Tuesday, September 10th. Leerink Partnrs analyst M. Foroohar now foreSeptember 12, 2024 | marketbeat.comIonis Pharmaceuticals: A Buy Rating with a Lowered Price Target Amidst Strong Growth ProspectsSeptember 11, 2024 | markets.businessinsider.comLeerink Partnrs Brokers Lift Earnings Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2028 EPS estimates for Ionis Pharmaceuticals in a report issued on Tuesday, September 10th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earningsSeptember 11, 2024 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down to $48.33Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down to $48.33September 10, 2024 | marketbeat.comRubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionSeptember 10, 2024 | benzinga.comIonis announces pricing of $500.3 million public offeringSeptember 9, 2024 | prnewswire.comIonis announces proposed public offering of common stockSeptember 9, 2024 | prnewswire.comCandriam S.C.A. Buys 36,369 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Candriam S.C.A. increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 4.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 948,266 shares of the company's stock aftSeptember 7, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-one research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have issued a hold rating,September 5, 2024 | marketbeat.comRichard S. Geary Sells 320 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockSeptember 4, 2024 | insidertrades.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $15,731.20 in StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Richard S. Geary sold 320 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $49.16, for a total value of $15,731.20. Following the transaction, the executive vice president now directly owns 85,154 shares in the company, valued at approximately $4,186,170.64. The transaction was disclosed in a filing with the SEC, which is available at this link.September 3, 2024 | marketbeat.com Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.690.43▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼56▲IONS Articles Average Week Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BHVN News Today RARE News Today JAZZ News Today BHC News Today PRGO News Today ACAD News Today ARWR News Today UTHR News Today INCY News Today EXAS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
